Patents by Inventor Petr Jansa

Petr Jansa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1?-cyano nucleoside analogs and uses thereof
    Patent number: 11939347
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: March 26, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Rao V. Kalla, Dmitry Koltun, Richard L. Mackman, Thao D. Perry, Dustin S. Siegel, Scott P. Simonovich
  • Inhibitors of peptidylarginine deiminases
    Patent number: 11878965
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: January 23, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Daniel H. Byun, Zhenhong R. Cai, Eda Y. Canales, Laurent P. Debien, Timothy R. Hansen, Richard Huang, Petr Jansa, Rick A. Lee, Jennifer A. Loyer-Drew, Ryan McFadden, Michael L. Mitchell, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Joshua J. Van Veldhuizen, Lianhong Xu
  • PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE
    Publication number: 20230303599
    Abstract: Compounds, compositions, and method useful for treating a viral infection, such as human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, are disclosed. In particular, prodrugs of phosphonamide nucleotide analogues and methods for their preparation and use as therapeutic or prophylactic agents are disclosed.
    Type: Application
    Filed: August 5, 2021
    Publication date: September 28, 2023
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Devan Naduthambi, Neil H. Squires
  • Antiviral compounds
    Patent number: 11767337
    Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: September 26, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Gregory F. Chin, Byoung-Kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Dustin S. Siegel, Hai Yang
  • ANTIVIRAL COMPOUNDS
    Publication number: 20230295201
    Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, and HCV.
    Type: Application
    Filed: February 21, 2023
    Publication date: September 21, 2023
    Inventors: Daniel H. Byun, Gregory F. Chin, Byoung-kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Michael R. Mish, Dustin S. Siegel, David Sperandio, Hai Yang, Lijun Zhang
  • Prodrugs of 4?-C-substituted-2-halo-2?- deoxyadenosine nucleosides and methods of making and using the same
    Patent number: 11718637
    Abstract: The present disclosure provides prodrugs of 4?-C-substituted-2-halo-2?-deoxyadenoside nucleosides, and compositions, methods, and kits thereof. Such compounds can be useful for treating viral infections including, but not limited to, human immunodeficiency virus.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: August 8, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Richard L. Mackman, Devan Naduthambi, Neil H. Squires
  • INHIBITORS OF PEPTIDYLARGININE DEIMINASES
    Publication number: 20230090053
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Application
    Filed: December 21, 2021
    Publication date: March 23, 2023
    Inventors: Daniel H. Byun, Zhenhong R. Cai, Eda Y. Canales, Laurent P. Debien, Timothy R. Hansen, Richard Huang, Petr Jansa, Rick A. Lee, Jennifer A. Loyer-Drew, Ryan McFadden, Michael L. Mitchell, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Joshua J. Van Veldhuizen, Lianhong Xu
  • KHK INHIBITORS
    Publication number: 20230079863
    Abstract: Compounds of formula: wherein the variable substituents are defined herein.
    Type: Application
    Filed: March 25, 2022
    Publication date: March 16, 2023
    Inventors: James L. Bachman, Daniel H. Byun, Christopher T. Clark, Petr Jansa, Joshua A. Kaplan, Zachary A. Kasun, Jennifer R. Lo, Megan E. Neubig, Nathaniel H. Stanley, Kirk L. Stevens
  • 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF
    Publication number: 20230040586
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Application
    Filed: June 23, 2021
    Publication date: February 9, 2023
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Rao V. Kalla, Dmitry Koltun, Richard L. Mackman, Thao D. Perry, Dustin S. Siegel, Scott P. Simonovich
  • Quinazoline Compounds
    Publication number: 20230043136
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Application
    Filed: March 9, 2022
    Publication date: February 9, 2023
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • INHIBITORS OF PEPTIDYLARGININE DEIMINASES
    Publication number: 20230002412
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Application
    Filed: April 28, 2021
    Publication date: January 5, 2023
    Inventors: Eda Y. Canales, Weng K. Chang, Laurent P. Debien, Petr Jansa, Jennifer A. Loyer-Drew, Luisruben P. Martinez, Stephane Perreault, Gary B. Phillips, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen
  • PRODRUGS OF 4'-C-SUBSTITUTED-2-HALO-2'-DEOXYADENOSINE NUCLEOSIDES AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20220363708
    Abstract: The present disclosure provides prodrugs of 4?-C-substituted-2-halo-2?-deoxyadenoside nucleosides, and compositions, methods, and kits thereof. Such compounds can be useful for treating viral infections including, but not limited to, human immunodeficiency virus.
    Type: Application
    Filed: March 19, 2021
    Publication date: November 17, 2022
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Richard L. Mackman, Devan Naduthambi, Neil H. Squires
  • ANTIVIRAL COMPOUNDS
    Publication number: 20220356196
    Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, and HCV.
    Type: Application
    Filed: February 16, 2021
    Publication date: November 10, 2022
    Inventors: Daniel H. Byun, Gregory F. Chin, Byoung-kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Michael R. Mish, Dustin S. Siegel, David Sperandio, Hai Yang, Lijun Zhang
  • INHIBITORS OF PEPTIDYLARGININE DEIMINASES
    Publication number: 20220227787
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Application
    Filed: December 21, 2021
    Publication date: July 21, 2022
    Inventors: Daniel H. Byun, Eda Y. Canales, Laurent P. Debien, Petr Jansa, Rick A. Lee, Jennifer A. Loyer-Drew, Stephane Perreault, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen, Lianhong Xu
  • PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE
    Publication number: 20220119426
    Abstract: Compounds, compositions, and method useful for treating a viral infection, such as human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, are disclosed. In particular, prodrugs of phosphonamide nucleotide analogues and methods for their preparation and use as therapeutic or prophylactic agents are disclosed.
    Type: Application
    Filed: August 5, 2021
    Publication date: April 21, 2022
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Devan Naduthambi, Neil H. Squires
  • Quinazoline compounds
    Patent number: 11304948
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: April 19, 2022
    Assignees: Gilead Sciences, Inc.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • ANTIVIRAL COMPOUNDS
    Publication number: 20210292348
    Abstract: The present disclosure describes 4?-fluoromethyl nucleosides for treating viral infections, including Dengue.
    Type: Application
    Filed: February 17, 2021
    Publication date: September 23, 2021
    Inventors: Daniel H. Byun, Gregory F. Chin, Michael O. Clarke, Bindu Goyal, Petr Jansa, Richard L. Mackman, Michael R. Mish, Dustin S. Siegel
  • ANTIVIRAL COMPOUNDS
    Publication number: 20210284670
    Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.
    Type: Application
    Filed: February 18, 2021
    Publication date: September 16, 2021
    Inventors: Gregory F. Chin, Byoung-Kwon Chun, Michael O. Clarke, Bindu Goyal, Hon C. Hui, Petr Jansa, Richard L. Mackman, Dustin S. Siegel, Hai Yang
  • Quinazoline Compounds
    Publication number: 20200360383
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Application
    Filed: December 18, 2019
    Publication date: November 19, 2020
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • Quinazoline compounds
    Patent number: 10548898
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: February 4, 2020
    Assignees: Gilead Sciences Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon